February 10, 2020 / 7:09 AM / 15 days ago

BRIEF-Eli Lilly And Dian-Tu Platform Trial Is A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study

Feb 10 (Reuters) - Eli Lilly and Co:

* TOPLINE RESULTS FOR SOLANEZUMAB FROM DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT (DIAN-TU) STUDY

* STUDY SHOWED THAT SOLANEZUMAB DID NOT MEET PRIMARY ENDPOINT

* ADDITIONAL ANALYSES OF SECONDARY ENDPOINTS AND BIOMARKERS ARE ONGOING BY WASHINGTON UNIVERSITY AND LILLY

* DIAN-TU PLATFORM TRIAL IS A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below